The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
2025 · Blood · 33 citations
https://doi.org/10.1182/blood.2024027506
M
Mei Dong
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
73
Papers
606
Citations
15
h-index
20
i10-index
Mei Dong is an academic researcher from Sichuan University. The author has contributed to research in topics: Respiratory viral infections research & Lymphoma Diagnosis and Treatment & Viral gastroenteritis research and epidemiology. The author has an h-index of 15, co-authored 63 publications.
ORCID: 0000-0002-9698-095XPapers by this author
worksLobar pneumonia caused by Ralstonia pickettii in a sixty-five-year-old Han Chinese man: a case report
2011 · Journal of Medical Case Reports · 15 citations
https://doi.org/10.1186/1752-1947-5-377
SARS-CoV-2–specific antibody and T-cell immunity in convalescents after infection wave in Beijing in late 2022
2023 · Journal of Infection · 10 citations
https://doi.org/10.1016/j.jinf.2023.08.010
YTHDF3as a prognostic predictive biomarker of thyroid cancer and its correlation with immune infiltration
2023 · BMC Cancer · 8 citations
https://doi.org/10.1186/s12885-023-11361-9
Human Enterovirus C105, China, 2017
2019 · Emerging infectious diseases · 4 citations
https://doi.org/10.3201/eid2507.180874
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat